Stryker Invests $400M in CMR Surgical, Secures U.S. Rights to Versius Robot
Stryker this week announced an approximately $400 million investment in CMR Surgical, the Cambridge, U.K.-based developer of the Versius surgical robotics platform. The deal includes an exclusive option for Stryker to acquire CMR Surgical’s remaining equity and an exclusive U.S. commercial agency agreement for the Versius portfolio.
CMR Surgical said it designed Versius to be compact and modular, so the system does not require a dedicated operating room. The platform features four carts with robotic arms, and its modular architecture is intended to support flexibility across procedures, surgeon access, and sites of care.
Massimiliano Colella, CEO of CMR Surgical, described the strategic alliance as a significant milestone for CMR and a strong endorsement of the technology, clinical experience, and global business the company has built. He said Stryker’s investment would give CMR additional strength to accelerate innovation and continue the global expansion of the Versius portfolio.
Colella added that Stryker’s scale and deep customer relationships create a significant growth opportunity in the United States.
The company said Versius can help healthcare providers grow robotic adoption within existing operating room workflows. This scalable approach can help health systems meet growing demand for robotic-assisted surgery while preserving operational flexibility and supporting long-term program economics, CMR Surgical said.
Versius supports procedures including general surgery, colorectal surgery, urology, gynecology, and thoracic surgery. According to CMR, the robot has been adopted in hospitals across more than 30 countries and used in 45,000 cases worldwide.
The Versius Plus system has earned FDA 510(k) clearance for cholecystectomy. CMR has also filed a 510(k) submission for benign gynecological indications, and the company said the robot has been used in 45,000 cases worldwide.
Stryker plans to sell the Versius system in the United States. Andy Pierce, group president of medsurg and neurotechnology at Stryker, said soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker’s strengths in endoscopy, visualization, and enabling technologies.
Pierce said Stryker has evaluated the segment carefully for years and views the alliance as a thoughtful and disciplined entry that combines the complementary strengths of both companies. He said Stryker selected CMR Surgical and the Versius portfolio because of the opportunity to help healthcare providers grow robotic-assisted surgery adoption across a broad range of procedures in hospitals and ambulatory surgery centers (ASCs).
Colella said CMR looks forward to welcoming Andy Pierce to its board of directors and benefiting from his more than 30 years of MedTech leadership experience at Stryker as CMR continues expanding access to robotic-assisted surgery globally.
Moving forward, Stryker will serve as the exclusive U.S. sales agent for the Versius portfolio, while CMR Surgical will continue to lead portfolio development and commercialization in markets outside the United States.
Stryker’s exclusive acquisition option gives it the right to buy 100% of CMR Surgical’s outstanding equity in the future, subject to the agreement’s terms. The transaction is subject to regulatory approvals and customary closing conditions.
RoboBusiness 2026 has opened its call for speakers as it celebrates 20 years of the event.
The original post appeared on The Robot Report.